Company Overview and News
Stop missing out on important events!
Abhijeet Das, Senior Associate, Singhania and Partners, opines that there are multiple fronts on which the aggrieved pharma companies can contest the ban
NEW YORK, Feb. 29, 2016 /PRNewswire/ -- This report on the inhalation and nasal spray generic drugs market studies...
FindLaw's searchable database of United States Sixth Circuit decisions since
Strong performance of Taro was the key contributor during the quarter. Higher other income and lower tax rate resulted in PAT being 4% higher than our estimates.
8 proposals deferred, 5 rejected by Foreign Investment Promotion Board
MUMBAI : Indian Bank is expected to report a 14% year-on-year fall in net profit for Oct-Dec at 2.38 bln rupees due to a likely rise in provisions,according to the average of the estimates of four brokerage houses.The public sector bank is scheduled to announce its earnings for Oct-Decon Thursday.Sequentially, the bottomline is seen falling 36%.”Expect 17% YoY growth in opex (operational expenditure), largely on a lower base (-5% YoY in the year-ago period)… elevated credit costs areexpected to result in PAT de-growth of (nearly) 35% YoY.
Net sales during the period under review stood at Rs 3,027.26 crore, up 15.33%.
Cipla Ltd, one of the leading drug makers in India, will announce its financial results on February 10. IIFL forecasts the company’s net revenue for Q3 FY16 to increase to Rs. 3,403 crore, growing at a rate of 23.1% yoy; however, it is likely to drop 1.4% qoq.
Hamied, who holds 15.54% in Cipla, will increase his stake to 20.76% once the proposal is approved
The Competition Commission of India has granted approval to the proposed investment by FIL Capital Investments (Mauritius) II Limited in Cipla Health Limited, subsidiary of the company, Cipla Ltd said in a regulatory filing. ..
Natco signed a pact with Medicines Patent Pool and Bristol-Myers Squibb to make and sell identical version of Daclatasvir, a drug used to treat hepatitis C
Securing the supply chain, environmental sustainability and updation of technology infrastructure will be the buzzwords. By Usha Sharma
Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more!
Drug major Cipla today announced the creation of a 6-member 'Management Council' that will be the apex executive leadership team for the company. Headed by Subhanu Saxena, Managing Director & Global Chief Executive Officer, the council will
This is part of the company's ongoing transformation journey to simplify decision making and improve operational excellence, Cipla Ltd said in a statement. .. (0-1)